Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of MD1003 in Spinal Progressive Multiple Sclerosis: a Pivotal Randomized Double Blind Placebo Controlled Study

NCT02220933 is registered in ClinicalTrials.gov with MedDay Pharmaceuticals SA as lead sponsor.

NCT NCT02220933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02220933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of MD1003 in Spinal Progressive Multiple Sclerosis: a Pivotal Randomized Double Blind Placebo Controlled Study
Lead sponsor
MedDay Pharmaceuticals SA
Phase
Phase 3
Overall status
Unknown status
Start date
October 31, 2013
Completion date
January 31, 2018
Enrollment
144 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis